Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

Arnulf Stenzl; Nigel C. Cowan; Maria De Santis; Markus A. Kuczyk; Axel S. Merseburger; Maria José Ribal; Amir Sherif; J. Alfred Witjes; Thierry Lebret

doi:10.1016/j.eururo.2012.04.042

Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, Markus A. Kuczyk, Axel S. Merseburger, Maria José Ribal, Amir Sherif, J. Alfred Witjes, Thierry Lebret

Klinik für Urologie

3 Zitate (Scopus)

Originalsprache	Englisch
Zeitschrift	European Urology
Jahrgang	62
Ausgabenummer	2
Seiten (von - bis)	45-46
Seitenumfang	2
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2012.04.042
Publikationsstatus	Veröffentlicht - 08.2012

Fördermittel

Dr. Stenzl is a company consultant for GE Healthcare and Novartis; has received speaker honoraria from Amgen and Novartis; has participated in trials for MEDAC, Photocure, Immatics, Novartis, Johnson & Johnson, Amgen, and Bayer; and has received research grants from Immatics. Dr. Witjes is a company consultant for Endo Pharm, Astellas, Spectrum Pharmaceuticals, Sanofi Pasteur, GE Healthcare, and Telormedix; has received speaker honoraria from GE Healthcare; and has participated in trials for MEL Amsterdam, Telormedix, and Photocure Oslo. Dr. Cowan has nothing to disclose. Dr. de Santis is a company consultant for Glaxo Smith Kline, Amgen, Bayer, Novartis, and Pierre-Fabre; has received speaker honoraria from Pfizer, Eli Lilly, Sanofi Aventis, Novartis, and Roche; has received fellowship and travel grants from Bayer, Novartis, Pfizer, Amgen, and Sanofi Aventis. Dr. Kuczyk has equity interests in Bayer Healtcare, Astellas, Storz, Pfizer, and Wyeth; is a company consultant for Bayer Healthcare, Pfizer, Astra Zeneca, Astellas, and Storz; has received speaker honoraria from Bayer, Pfizer, Medac, Astellas, Bayer Healthcare, and Astellas; has participated in trials for Astra Zeneca, Pfizer, Bayer Healthcare, Astellas, and Ipsen; and has received research grants from Wyeth. Dr. Merseburger is a company consultant for Ipsen Pharma and Bayer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for Astra Zeneca, Bayer, Pfizer, TEVA, and Novartis; and has received research grants from Wyeth. Dr. Sherif has received speaker honoraria from Orion Pharma and MEDAC AB. Dr. Lebret is a company consultant for Ipsen, Amgen, Sanofi, and Novartis; has received speaker honoraria from Ferring; and has participated in trials for Astellas and Takeda.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

Dokumente

10.1016/j.eururo.2012.04.042

Weitere Links

Link to publication in Scopus

Zitieren

Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., Witjes, J. A., & Lebret, T. (2012). Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18. European Urology, 62(2), 45-46. https://doi.org/10.1016/j.eururo.2012.04.042

@article{25c031e037a34800b4595d86c270b2e8,

title = "Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18",

author = "Arnulf Stenzl and Cowan, \{Nigel C.\} and \{De Santis\}, Maria and Kuczyk, \{Markus A.\} and Merseburger, \{Axel S.\} and Ribal, \{Maria Jos{\'e}\} and Amir Sherif and Witjes, \{J. Alfred\} and Thierry Lebret",

note = "Funding Information: Dr. Stenzl is a company consultant for GE Healthcare and Novartis; has received speaker honoraria from Amgen and Novartis; has participated in trials for MEDAC, Photocure, Immatics, Novartis, Johnson \& Johnson, Amgen, and Bayer; and has received research grants from Immatics. Dr. Witjes is a company consultant for Endo Pharm, Astellas, Spectrum Pharmaceuticals, Sanofi Pasteur, GE Healthcare, and Telormedix; has received speaker honoraria from GE Healthcare; and has participated in trials for MEL Amsterdam, Telormedix, and Photocure Oslo. Dr. Cowan has nothing to disclose. Dr. de Santis is a company consultant for Glaxo Smith Kline, Amgen, Bayer, Novartis, and Pierre-Fabre; has received speaker honoraria from Pfizer, Eli Lilly, Sanofi Aventis, Novartis, and Roche; has received fellowship and travel grants from Bayer, Novartis, Pfizer, Amgen, and Sanofi Aventis. Dr. Kuczyk has equity interests in Bayer Healtcare, Astellas, Storz, Pfizer, and Wyeth; is a company consultant for Bayer Healthcare, Pfizer, Astra Zeneca, Astellas, and Storz; has received speaker honoraria from Bayer, Pfizer, Medac, Astellas, Bayer Healthcare, and Astellas; has participated in trials for Astra Zeneca, Pfizer, Bayer Healthcare, Astellas, and Ipsen; and has received research grants from Wyeth. Dr. Merseburger is a company consultant for Ipsen Pharma and Bayer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for Astra Zeneca, Bayer, Pfizer, TEVA, and Novartis; and has received research grants from Wyeth. Dr. Sherif has received speaker honoraria from Orion Pharma and MEDAC AB. Dr. Lebret is a company consultant for Ipsen, Amgen, Sanofi, and Novartis; has received speaker honoraria from Ferring; and has participated in trials for Astellas and Takeda. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.",

year = "2012",

month = aug,

doi = "10.1016/j.eururo.2012.04.042",

language = "English",

volume = "62",

pages = "45--46",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Stenzl, A, Cowan, NC, De Santis, M, Kuczyk, MA, Merseburger, AS, Ribal, MJ, Sherif, A, Witjes, JA & Lebret, T 2012, 'Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18', European Urology, Jg. 62, Nr. 2, S. 45-46. https://doi.org/10.1016/j.eururo.2012.04.042

Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18. / Stenzl, Arnulf; Cowan, Nigel C.; De Santis, Maria et al.
in: European Urology, Jahrgang 62, Nr. 2, 08.2012, S. 45-46.

Publikation: Beiträge in Fachzeitschriften › Briefe › Begutachtung

TY - JOUR

T1 - Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

AU - Stenzl, Arnulf

AU - Cowan, Nigel C.

AU - De Santis, Maria

AU - Kuczyk, Markus A.

AU - Merseburger, Axel S.

AU - Ribal, Maria José

AU - Sherif, Amir

AU - Witjes, J. Alfred

AU - Lebret, Thierry

N1 - Funding Information: Dr. Stenzl is a company consultant for GE Healthcare and Novartis; has received speaker honoraria from Amgen and Novartis; has participated in trials for MEDAC, Photocure, Immatics, Novartis, Johnson & Johnson, Amgen, and Bayer; and has received research grants from Immatics. Dr. Witjes is a company consultant for Endo Pharm, Astellas, Spectrum Pharmaceuticals, Sanofi Pasteur, GE Healthcare, and Telormedix; has received speaker honoraria from GE Healthcare; and has participated in trials for MEL Amsterdam, Telormedix, and Photocure Oslo. Dr. Cowan has nothing to disclose. Dr. de Santis is a company consultant for Glaxo Smith Kline, Amgen, Bayer, Novartis, and Pierre-Fabre; has received speaker honoraria from Pfizer, Eli Lilly, Sanofi Aventis, Novartis, and Roche; has received fellowship and travel grants from Bayer, Novartis, Pfizer, Amgen, and Sanofi Aventis. Dr. Kuczyk has equity interests in Bayer Healtcare, Astellas, Storz, Pfizer, and Wyeth; is a company consultant for Bayer Healthcare, Pfizer, Astra Zeneca, Astellas, and Storz; has received speaker honoraria from Bayer, Pfizer, Medac, Astellas, Bayer Healthcare, and Astellas; has participated in trials for Astra Zeneca, Pfizer, Bayer Healthcare, Astellas, and Ipsen; and has received research grants from Wyeth. Dr. Merseburger is a company consultant for Ipsen Pharma and Bayer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for Astra Zeneca, Bayer, Pfizer, TEVA, and Novartis; and has received research grants from Wyeth. Dr. Sherif has received speaker honoraria from Orion Pharma and MEDAC AB. Dr. Lebret is a company consultant for Ipsen, Amgen, Sanofi, and Novartis; has received speaker honoraria from Ferring; and has participated in trials for Astellas and Takeda. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.

PY - 2012/8

Y1 - 2012/8

UR - https://www.scopus.com/pages/publications/84862856868

U2 - 10.1016/j.eururo.2012.04.042

DO - 10.1016/j.eururo.2012.04.042

M3 - Letters

C2 - 22579356

AN - SCOPUS:84862856868

SN - 0302-2838

VL - 62

SP - 45

EP - 46

JO - European Urology

JF - European Urology

IS - 2

ER -

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ et al. Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18. European Urology. 2012 Aug;62(2):45-46. doi: 10.1016/j.eururo.2012.04.042